Suppliers / Glenmark Generics

Glenmark Generics

Argentina Updated 9 July 2026

Glenmark Generics is a finished-dose manufacturer based in Argentina. It appears in 13 regulatory filings across 1 regulator, without an active US DMF or CEP on file. Its GMP standing is certified by ANVISA (Brazil). Its most recent recorded inspection, by US FDA, closed on 27 May 2014 as VAI. Customs aggregates show $6.0M of exports covering 77 molecules to 11 destinations in 2025.

0
active US DMFs
0
valid CEPs
2
registered plants 1 with an FDA FEI number
13
filings across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 27 May 2014 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
BUENOS AIRES, Argentina Not on file
Argentina, Argentina 3009805225

Filings and GMP by regulator

Regulator Filings GMP certificates
ANMAT (AR) 13 None
ANVISA (Brazil) None 1

Scale

Year Revenue Exports Destinations
2025 Not reported $6.0M 11
2024 Not reported $10.5M 13
2023 Not reported $3.2M 13
2022 Not reported $5.4M 12

Export figures are customs aggregates. We do not publish the identity of any buyer.

Comparing suppliers?

Choose your molecules and target markets. Glenmark Generics comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 27 May 2014.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Customs aggregates
Export values, molecule and destination counts